This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Koivisto, P. Articles by Kallioniemi, O. P. Search for Related Content PubMed PubMed Citation Articles by Koivisto, P. Articles by Kallioniemi, O. P.

American Journal of Pathology, Vol 147, 1608-1614, Copyright © 1995 by American Society for Investigative Pathology

REGULAR ARTICLES

Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy

P Koivisto, E Hyytinen, C Palmberg, T Tammela, T Visakorpi, J Isola and OP Kallioniemi
Laboratory of Cancer Genetics, Tampere University, Institute of Medical Technology, Finland.

The molecular mechanisms and genetic changes that lead to the progression of prostate cancer during endocrine therapy are poorly characterized. Here, paired specimens from both untreated primary tumors and from local recurrences were collected from 10 prostate cancer patients treated by conventional androgen deprivation therapy. The genetic progression of the tumors was studied by using interphase fluorescence in situ hybridization and chromosome-specific probes. Six primary tumors (60%) and all ten recurrent tumors were aneuploid by fluorescence in situ hybridization. The recurrent tumors also showed a high degree of chromosome copy number variability from one cell to another. Increased copy number of chromosome X was particularly common in the recurrent tumors. In addition, specific high level amplification of the androgen receptor (AR) gene (Xq12) was detected in three highly aneuploid recurrent tumors. Our findings suggest that hormone- refractory prostate cancers are genetically very complex and show intratumor genetic heterogeneity. Increased copy number of chromosome X and the amplification of the androgen receptor (AR) gene may confer proliferative advantage during androgen deprivation and thus contribute to the development of recurrence.

This article has been cited by other articles:

				B. He, R. T. Gampe Jr., A. T. Hnat, J. L. Faggart, J. T. Minges, F. S. French, and E. M. Wilson Probing the Functional Link between Androgen Receptor Coactivator and Ligand-binding Sites in Prostate Cancer and Androgen Insensitivity J. Biol. Chem., March 10, 2006; 281(10): 6648 - 6663. [Abstract] [Full Text] [PDF]

				P Dai and L-J C Wong Somatic instability of the DNA sequences encoding the polymorphic polyglutamine tract of the AIB1 gene J. Med. Genet., December 1, 2003; 40(12): 885 - 890. [Abstract] [Full Text]

				C.-Y. Chang, P. J. Walther, and D. P. McDonnell Glucocorticoids Manifest Androgenic Activity in a Cell Line Derived from a Metastatic Prostate Cancer Cancer Res., December 1, 2001; 61(24): 8712 - 8717. [Abstract] [Full Text] [PDF]

				J. W. Gray and C. Collins Genome changes and gene expression in human solid tumors Carcinogenesis, March 1, 2000; 21(3): 443 - 452. [Abstract] [Full Text] [PDF]

				N. M. Navone, M. d. C. Rodriguez-Vargas, W. F. Benedict, P. Troncoso, T. J. McDonnell, J.-H. Zhou, R. Luthra, and C. J. Logothetis TabBO: A Model Reflecting Common Molecular Features of Androgen-independent Prostate Cancer Clin. Cancer Res., March 1, 2000; 6(3): 1190 - 1197. [Abstract] [Full Text]